This advisory defines protracted withdrawal and identifies specific withdrawal symptoms associated with alcohol, opioids, methamphetamine, cocaine, marijuana, and benzodiazepines. The advisory also explains how protracted withdrawal differs from acute withdrawal, and gives tips to help clients manage it in recovery.
You May Also Be Interested In
Advisory: An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People with Opioid Dependence
This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.
Advisory: Hepatitis C Screening in the Behavioral Healthcare Setting
This advisory provides information about screening for Hepatitis C. It defines Hepatitis C and discusses its prevalence and transmission. The advisory also describes methods for treatment, testing, and counseling.
Advisory: Complementary Health Approaches
This advisory for behavioral health practitioners provides a brief overview of complementary health approaches. It describes the practices and products that are considered complementary, and explains how practitioners can help patients understand the benefits and risks.
Advisory: Adults With Attention Deficit Hyperactivity Disorder and Substance Use Disorders
This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.
Advisory: An Introduction to Bipolar Disorder and Co-Occurring Substance Use Disorders
This advisory gives an introduction to bipolar disorder and co-occurring substance use disorder. It discusses types of bipolar disorders along with the challenges in screening and treatments.
Advisory: Implementing Tobacco Cessation Treatment for Individuals with Serious Mental Illness: A Quick Guide for Program Directors and Clinicians
This Advisory can help clinicians who work in a mental health facility implement a tobacco cessation program to reduce the use of tobacco-related products and tobacco-related diseases among clients with SMI.